Stock Market & Financial Investment News

News Breaks January 29, 2013 08:19 EDT BSX Boston Scientific to expand restructuring, sees cutting 900-1,000 jobs The company announced earlier an expansion of its 2011 restructuring program. The company estimates that the Expansion will reduce gross annual pre-tax operating expenses by approximately $100M-$115M exiting 2013; and that the total 2011 restructuring program, including the Expansion, will reduce gross annual pre-tax operating expenses by approximately $340M-$375M exiting 2013. The company anticipates the reduction of 900 to 1,000 positions worldwide through a combination of employee attrition and targeted headcount reductions as a result of the Expansion. The company estimates that the implementation of the Expansion will result in total pre-tax charges of approximately $140M-$160M, and that approximately $100M-$120M of these charges will result in future cash outlays. The company estimates that the implementation of the Total Program will result in total pre-tax charges of approximately $300M-$355M, and that approximately $270M-$300M of these charges will result in future cash outlays. News For BSX From The Last 14 Days Check below for free stories on BSX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 09:41 EDT BSX Supreme Court agrees to hear Medtronic-Boston Scientific patent case Reported by SCOTUSblog live blog of court orders and opinions. May 16, 2013 16:13 EDT BSX Vascular Solutions files patent infringement complaint against Boston Scientific Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. 07:51 EDT BSX Boston Scientific price target raised to $12 from $9 at JMP Securities JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. 07:28 EDT BSX I/O Central to host a conference Subscribe for More Information May 14, 2013 15:33 EDT BSX Boston Scientific has a conference call hosted by JPMorgan JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. May 10, 2013 10:00 EDT BSX On The Fly: Analyst Upgrade Summary Subscribe for More Information 09:03 EDT BSX Boston Scientific receives CEO Mark approval for Rhythmia mapping system Subscribe for More Information 05:46 EDT BSX Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo Subscribe for More Information May 9, 2013 12:04 EDT BSX Boston Scientific says data show Watchman device superior to warfarin Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. 09:27 EDT BSX Leerink's medical devices analyst holds a conference call Subscribe for More Information May 8, 2013 07:38 EDT BSX BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.